Androgen deprivation combined with external beam radiotherapy improves the overall survival of patients with localized prostate cancer but might be associated with adverse effects that influence their health and quality of life. When considering this medication, clinicians must be aware of the increased risk of cardiac mortality in patients with moderate or severe comorbidity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
D'Amico, A. V., Chen, M. H., Renshaw, A. A., Loffredo, M. & Kantoff, P. W. Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA 314, 1291–1293 (2015).
D'Amico, A. V., Chen, M. H., Renshaw, A. A., Loffredo, M. & Kantoff, P. W. Androgen suppression and radiation versus radiation alone for prostate cancer: a randomized trial. JAMA 299, 289–295 (2008).
Sean O'Farrell, S. et al. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J. Clin. Oncol. 33, 1243–1251 (2015).
Efstathiou, J. A. et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer. J. Clin. Oncol. 27, 92–99 (2008).
Bolla, M. et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 11, 1066–1073 (2010).
Efstathiou, J. A. et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur. Urol. 54, 816–824 (2008).
Bolla, M. et al. Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med. 360, 2516–2527 (2009).
Nguyen, P. L. et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306, 2359–2366 (2011).
Nguyen, P. L. et al. Influence of androgen deprivation therapy on all causes mortality in men with high risk prostate cancer and a history of a congestive heart failure or myocardial infarction. Int. J. Radiat. Oncol. Biol. Phys. 82, 1411–1416 (2012).
Levine, G. N. et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121, 833–840 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.B. declares that he has received travel support from Janssen and Ipsen and that he has received lecture fees from AstraZeneca. G.C. declares no competing interests.
Rights and permissions
About this article
Cite this article
Bolla, M., Créhange, G. Cardiac mortality associated with ADT plus radiotherapy. Nat Rev Urol 13, 128–129 (2016). https://doi.org/10.1038/nrurol.2015.295
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2015.295
